Last edition
News about "Valneva "
Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy
Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.
Valneva | 24/03/2026 | By News Bureau
Valneva and Serum Institute End Chikungunya Vaccine Licensing Deal
Valneva SE and the Serum Institute of India have mutually agreed to discontinue their licensing agreement for Valneva’s single-shot chikungunya vaccine, bringing the collaboration to a close by mutual consent.
Valneva | 01/01/2026 | By News Bureau
Valneva to Further Consolidate its Operations in France
The move is part of Valneva’s strategy to optimise its global footprint, enhance operational efficiency in France, and unify all research and development efforts at its Vienna hub.
Valneva | 28/11/2025 | By Dineshwori | 202
Valneva Names Dr. Hanneke Schuitemaker as Chief Scientific Officer
Valneva has appointed Dr. Hanneke Schuitemaker, PhD as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024.
Valneva | 22/05/2024 | By Aishwarya | 459
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy